How should I manage a patient with atrial fibrillation, heart rate 57 bpm, who is taking apixaban (Eliquis)?

Management of Atrial Fibrillation with Heart Rate 57 bpm on Apixaban

Continue Apixaban Without Interruption

Your patient's anticoagulation is appropriate and must not be stopped. Apixaban 5 mg twice daily (or 2.5 mg twice daily if she meets dose-reduction criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL—any 2 of these 3 factors) should be continued indefinitely based on her stroke risk, not her heart rate or rhythm status. 1

• Direct oral anticoagulants like apixaban are preferred over warfarin in atrial fibrillation because they lower intracranial hemorrhage risk and have predictable pharmacokinetics. 2
• In the ARISTOTLE trial, apixaban was superior to warfarin for stroke prevention and caused fewer major bleeding events in patients with atrial fibrillation. 1
• Stroke risk is determined by the CHA₂DS₂‑VASc score (congestive heart failure, hypertension, age ≥75 years [2 points], diabetes, prior stroke/TIA [2 points], vascular disease, age 65–74, female sex), not by heart rate or rhythm. 2

---

Assess for Reversible Causes of Bradycardia

Before adjusting any therapy, identify why her heart rate is 57 bpm. Review all medications that block AV-nodal conduction and check for metabolic or structural causes. 2

Medication Review

• Beta-blockers (metoprolol, atenolol, bisoprolol, carvedilol, propranolol) are the most common culprits of excessive bradycardia in atrial fibrillation. 2
• Non-dihydropyridine calcium-channel blockers (diltiazem, verapamil) also slow AV-nodal conduction and can cause resting bradycardia. 2
• Digoxin frequently causes bradycardia, especially when combined with other AV-nodal blockers or in the setting of renal impairment; measure serum digoxin concentration if she is taking it. 2
• Amiodarone produces symptomatic bradycardia, particularly in elderly patients or those with paroxysmal atrial fibrillation. 2

Metabolic and Structural Evaluation

• Check thyroid function (hypothyroidism), electrolytes (hyperkalemia), and renal function (digoxin accumulation). 2
• Obtain a 12-lead ECG to assess for intrinsic sinus node dysfunction, high-grade AV block, or other conduction abnormalities. 2
• If bradycardia persists after medication adjustment or occurs in the absence of rate-control drugs, suspect intrinsic sinus node or AV-node disease. 2

---

Determine Whether Bradycardia Is Symptomatic

Hemodynamically Unstable (Immediate Action Required)

If she has symptomatic hypotension (systolic BP <90 mmHg), altered mental status, acute heart failure, ongoing chest pain, or shock, this is a medical emergency. 2

• Administer atropine 0.5–1 mg IV (repeatable to a total of 3 mg) as a bridge while arranging transcutaneous or transvenous pacing. 2
• Use specific reversal agents if medication toxicity is suspected: glucagon for beta-blocker overdose and calcium chloride for calcium-channel blocker toxicity. 2
• Do not perform electrical cardioversion in the setting of digitalis toxicity or hypokalemia, as it may precipitate ventricular arrhythmias. 2

Hemodynamically Stable (Medication Adjustment)

If she is asymptomatic or mildly symptomatic (fatigue, mild dizziness) with stable blood pressure, reduce or discontinue the offending rate-control agent. 2

• Reduce the dose of beta-blocker, calcium-channel blocker, or digoxin by 50% and reassess heart rate in 3–7 days. 2
• Discontinue digoxin if toxicity is suspected (nausea, visual disturbances, confusion); treat severe cases with digoxin-specific antibody fragments (Digibind). 2
• Avoid artificially increasing heart rate with pharmacologic agents in stable patients; instead, address the underlying cause. 2

---

Rate-Control Target: Lenient Is Acceptable

A resting heart rate of 57 bpm is below the lenient target of <110 bpm but may be acceptable if she is asymptomatic. 2

• The initial lenient resting heart-rate goal is <110 bpm; a stricter target of <80 bpm is pursued only if symptoms persist despite achieving the lenient goal. 2
• Assess heart rate during exertion, not solely at rest, because many patients have inadequate control during activity despite acceptable resting rates. 2
• If she is asymptomatic at rest and during normal daily activities, no further rate-control adjustment is needed. 2

---

Long-Term Management Strategy

Continue Rate Control (Preferred Strategy)

Rate control combined with chronic anticoagulation is as effective as rhythm control for reducing mortality and cardiovascular events, with fewer adverse effects and hospitalizations. 2

• For patients with preserved ejection fraction (LVEF >40%), beta-blockers or non-dihydropyridine calcium-channel blockers are first-line agents. 2
• For patients with reduced ejection fraction (LVEF ≤40%) or heart failure, use only beta-blockers (bisoprolol, carvedilol, long-acting metoprolol) and/or digoxin; avoid diltiazem and verapamil because of negative inotropic effects. 2
• Digoxin alone is ineffective for rate control during exercise or sympathetic surges and should never be used as monotherapy. 2

Consider Rhythm Control Only If Symptomatic Despite Adequate Rate Control

Rhythm-control strategies (antiarrhythmic drugs or catheter ablation) should be considered only if she remains symptomatic despite optimal rate control, is younger (<65 years) with new-onset atrial fibrillation, has rate-related cardiomyopathy, or is hemodynamically unstable. 2

• Rhythm control does not reduce mortality compared with rate control and is associated with higher hospitalization and adverse drug-effect rates in older patients. 2
• For patients without structural heart disease, flecainide, propafenone, or sotalol are first-line antiarrhythmic agents. 2
• For patients with heart failure or LVEF ≤40%, amiodarone or dofetilide are the only safe antiarrhythmic options because other agents carry high pro-arrhythmic risk. 2

---

Permanent Pacemaker Consideration

If she develops symptomatic bradycardia that requires ongoing rate-control therapy for atrial fibrillation, permanent pacemaker implantation is indicated. 2

• AV-node ablation with pacemaker implantation should be considered when maximal pharmacologic rate control fails or is not tolerated. 2
• In patients with permanent atrial fibrillation and heart failure, combining AV-node ablation with cardiac resynchronization therapy may provide additional benefit. 2

---

Common Pitfalls to Avoid

• Do not discontinue apixaban solely because her heart rate is controlled or she appears to be in sinus rhythm; stroke risk is determined by CHA₂DS₂‑VASc score, not rhythm status. 2
• Do not pharmacologically increase heart rate in stable patients with medication-induced bradycardia; instead, reduce or stop the offending agent. 2
• Do not combine beta-blockers with diltiazem or verapamil except under specialist supervision, as the risk of severe bradycardia and heart block is substantial. 2
• Do not perform electrical cardioversion in patients with digitalis toxicity or hypokalemia because of the risk of ventricular arrhythmias. 2